Kyverna Technologies are bringing curative living medicines to life to free patients from the siege of autoimmune disease.
Total raised: $255M
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | Vida Ventu... | vidaventur... |
| 25.06.2022 | Insight Pa... | insightpar... |
| 28.05.2024 | Bain Capit... | baincapita... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.08.2023 | Series B | $145M | - |
| 26.01.2022 | Series B | $85M | - |
| 14.01.2020 | Series A | $25M | - |
Mentions in press and media 18
| Date | Title | Description |
| 10.02.2024 | Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering | - |
| 09.02.2024 | Upsized Kyverna IPO Gets $319M to Bring CAR T-Therapy to Autoimmune Diseases | When cell therapy first reached patients as targeted treatment for the toughest cases of blood cancer, scientists thought this novel therapeutic modality might also find use in autoimmune conditions. The challenge was making these therapies... |
| 08.02.2024 | Gilead sours on the ‘don’t eat me’ business | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech s... |
| 13.12.2023 | Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis | - |
| 04.08.2023 | USA-based Kyverna Therapeutics extends Series B round to USD 145 million | California, USA-based clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases, Kyverna Therapeutics, closed its Series B extension at USD 60 million. The company announced the clo... |
| 03.08.2023 | Kyverna Raises $60M Series B Extension | EMERYVILLE, CA, Kyverna Therapeutics today announced the close of an oversubscribed $60 million Series B financing round extension. >> Click here for more funding data on Kyverna Therapeutics >> To export Kyverna Therapeutic... |
| 03.08.2023 | Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors | - |
| 03.08.2023 | Kyverna Therapeutics Raises $60M Series B Extension; Series B to $145M | Kyverna Therapeutics, an Emeryville, CA-based clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases, closed a $60m Series B financing round extension, bringing the total Series ... |
| 27.01.2022 | Kyverna Therapeutics Closes $85M Series B | EMERYVILLE, CA, Kyverna Therapeutics, a cell therapy company, has closed an oversubscribed $85M Series B financing round led by Northpond Ventures. >> Click here for more funding data on Kyverna Therapeutics >> To export Kyv... |
| 26.01.2022 | Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising | Gilead Sciences has tagged along on Kyverna Therapeutics’ journey as a startup since the beginning, and, now, the Big Pharma has helped stock up the cell therapy biotech in an $85 million financing round to prepare for a launch into the cli... |
Show more